



# Corrigendum to “Health Care Workers Need COVID-19 Vaccination: Clinical, Public Health and Ethical Considerations” *The American Journal of Medicine* Vol. 134:12 p1437–1439

Dennis G. Maki, MD,<sup>a</sup> Charles H. Hennekens, MD, DrPH<sup>b</sup>

<sup>a</sup>Professor of Medicine and Director of the COVID-19 Intensive Care Unit, University of Wisconsin School of Medicine and Public Health, Madison; <sup>b</sup>First Sir Richard Doll Professor & Senior Academic Advisor to the Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Fla.

The authors regret that an error was made in the third paragraph of the article. That paragraph should read as follows:

Clinicians should be aware of the similarities and differences between the usual bouts of influenza and COVID-19. First and foremost, the mortality rate from COVID-19 is about 30 times higher. Second, a positive COVID-19 patient is likely to transmit to about 6 people compared with 1 or 2 for influenza. Third, the efficacy of COVID-19 vaccines are 95% which is significantly higher than for conventional influenza vaccine. Fourth, the COVID-19 vaccine offers almost complete protection against hospitalization, admission to intensive care units and death. Fifth, breakthrough infections in fully vaccinated individuals are

associated with a reduced viral load which is cleared more rapidly and are considered to be less likely to transmit COVID-19 than primary infections in non-vaccinated individuals.<sup>3</sup> Last, but not least, the side effects of the COVID-19 vaccine are far less than for influenza. Specifically, serious side effects occur in the range of 1 per million doses.

Reference number 3 should be listed correctly as follows:

3. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med.* 2021;27:790–792. <https://doi.org/10.1038/s41591-021-01316-7>.

The authors are indebted to Nadine Nixon, MD, for detecting and reporting this error.

**Funding:** None.

**Conflicts of Interest:** Professor Maki has no disclosures. Professor Hennekens reports that he serves as an independent scientist in an advisory role to investigators and sponsors as Chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; to the Collaborative Institutional Training Initiative (CITI), legal counsel for Pfizer, the United States Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women’s Hospital; has an investment management relationship with the West-Bacon Group within Truist Investments, which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company.

**Authorship:** Both authors had access to the data and a role in writing this manuscript.

Correspondence In addition should be addressed to Charles H. Hennekens, MD, DrPH, First Sir Richard Doll Professor & Senior Academic Advisor to the Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University, 2800 S. Ocean Blvd. PHA, Boca Raton, FL, 33432.

E-mail address: [chenneke@health.fau.edu](mailto:chenneke@health.fau.edu)